What Is GHRP-6? (Growth Hormone Release Mechanism)
Fewer than 12% of peptide research protocols that claim to study growth hormone secretagogues actually verify the amino-acid sequence of the compounds they're testing. Which means most published variability in GHRP-6 outcomes stems from impurity, not biology. When a peptide like GHRP-6 (Growth Hormone-Releasing Peptide-6) is synthesized with exact sequencing and verified purity above 98%, the growth hormone response becomes remarkably consistent across mammalian models. The difference between research-grade GHRP-6 and generic peptide powder isn't subtle. It's the difference between replicable data and noise.
At Real Peptides, we've supplied GHRP-6 to hundreds of research institutions conducting metabolic, neurological, and endocrine studies. The most common question we receive isn't about dosage or reconstitution. It's about why results from one supplier's GHRP-6 don't match results from another's. The answer is purity, sequencing precision, and storage integrity.
What is GHRP-6?
GRHP-6 is a synthetic hexapeptide (six amino acids: His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) that functions as a ghrelin receptor agonist, binding to growth hormone secretagogue receptors (GHS-R1a) in the pituitary gland and hypothalamus to stimulate endogenous growth hormone release. Unlike exogenous growth hormone administration, GHRP-6 preserves the body's natural pulsatile secretion pattern, making it a cornerstone compound in research studying metabolic regulation, tissue repair signaling, and neuroendocrine feedback loops.
Most peptide overview guides stop at the receptor-binding explanation. That's insufficient. GHRP-6 doesn't just bind to GHS-R1a receptors. It does so with significantly higher affinity than the body's endogenous ghrelin, which is why subcutaneous administration of 100–300 mcg GHRP-6 in rodent models produces growth hormone peaks 5–15 times baseline within 15–30 minutes of injection. This article covers the precise molecular mechanism that makes GHRP-6 effective, how amino-acid sequencing errors destroy receptor affinity, what separates research-grade synthesis from bulk powder production, and why storage protocol matters as much as purity at the point of manufacture.
GHRP-6 Mechanism: Ghrelin Mimicry and Growth Hormone Pulsatility
GRHP-6 works by mimicking ghrelin, the endogenous peptide hormone produced primarily in the stomach that signals hunger and regulates growth hormone secretion. Ghrelin binds to GHS-R1a receptors located on somatotroph cells in the anterior pituitary gland. Once bound, the receptor activates intracellular signaling cascades (primarily through Gq protein coupling and calcium mobilization) that trigger the release of growth hormone from stored vesicles into systemic circulation. GHRP-6 replicates this mechanism with one critical advantage: it resists enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV) and other proteases that rapidly degrade natural ghrelin, extending the duration and magnitude of receptor activation.
The hexapeptide sequence of GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) contains two D-amino acids. D-tryptophan at position 2 and D-phenylalanine at position 5. Which are unnatural stereoisomers that confer protease resistance. Natural ghrelin, composed entirely of L-amino acids, has a circulating half-life of approximately 30 minutes; GHRP-6, by contrast, maintains receptor-binding activity for 90–120 minutes post-administration in rodent pharmacokinetic studies. This extended activity window is why GHRP-6 produces more sustained growth hormone elevation than endogenous ghrelin pulses. The receptor remains occupied longer, and the signaling cascade continues until the peptide is cleared or internalized.
Growth hormone release following GHRP-6 administration follows a dose-dependent curve. Published studies in rat models demonstrate that subcutaneous doses of 100 mcg/kg produce growth hormone levels 8–12 times baseline at 20-minute post-injection, while doses of 300 mcg/kg produce peaks 15–20 times baseline. The response is not linear. Doubling the dose does not double the growth hormone peak, because receptor saturation begins above 200 mcg/kg in most mammalian models. Understanding this saturation threshold is critical for designing protocols that maximize biological response without wasting compound through supraphysiological dosing.
Here's what most peptide summaries don't explain: GHRP-6 also exhibits mild orexigenic (appetite-stimulating) effects independent of growth hormone release, because GHS-R1a receptors exist not only in the pituitary but also in the hypothalamic arcuate nucleus, which regulates hunger signaling. Rodent studies using GHRP-6 at doses above 150 mcg/kg consistently show increased food intake within 60–90 minutes of administration. This is a ghrelin-mimetic effect, not a growth hormone effect. Researchers studying metabolic outcomes must account for this confounding variable, particularly in feeding studies or body composition protocols where caloric intake is a controlled parameter.
At Real Peptides, every batch of GHRP-6 is synthesized through solid-phase peptide synthesis with individual amino-acid coupling verified at each step. The D-amino acid incorporation at positions 2 and 5 is what separates functional GHRP-6 from inactive peptide fragments, and sequencing errors at either position eliminate receptor affinity entirely.
Synthesis Precision: Why Amino-Acid Sequencing Errors Destroy GHRP-6 Efficacy
The biological activity of GHRP-6 is entirely dependent on exact amino-acid sequencing and stereochemical configuration. A single substitution. Replacing D-tryptophan with L-tryptophan, or omitting the C-terminal amide group (the -NH2 modification on lysine). Reduces receptor-binding affinity by 70–90% and accelerates enzymatic degradation to the point where the peptide is cleaved before reaching target receptors. This is not a theoretical concern. It's the primary reason research outcomes using GHRP-6 from low-purity suppliers show inconsistent growth hormone responses.
Solid-phase peptide synthesis (SPPS), the method used to produce research-grade GHRP-6, involves sequentially coupling amino acids to a growing peptide chain anchored to a solid resin. Each coupling step must reach >99% completion before the next amino acid is added. Incomplete coupling leaves truncated peptide fragments (deletion sequences) that cannot bind to GHS-R1a receptors. After synthesis, the peptide is cleaved from the resin, purified using reverse-phase high-performance liquid chromatography (RP-HPLC), and analyzed by mass spectrometry to confirm the molecular weight matches the target sequence exactly. Peptides that pass this verification are then lyophilized (freeze-dried) to remove water and prevent hydrolysis during storage.
The purity percentage reported on a certificate of analysis (CoA) reflects the proportion of the sample that is the correct target peptide versus truncated sequences, synthesis byproducts, or residual solvents. GHRP-6 at 95% purity means 5% of the sample is not GHRP-6. It's deletion sequences, acetylated fragments, or trifluoroacetic acid (TFA) salts from the purification process. Research-grade GHRP-6 should exceed 98% purity by HPLC, with mass spectrometry confirmation showing a single dominant peak at the expected molecular weight of 872.44 Da (for the acetate salt form).
Here's the blunt reality: generic peptide suppliers that don't publish batch-specific CoAs or provide HPLC chromatograms are almost certainly selling peptides with purity below 90%, and many contain significant amounts of des-amino variants (missing one or more amino acids from the sequence). A des-Lys GHRP-6 variant (missing the lysine at position 6) has nearly zero GHS-R1a binding affinity, because the lysine residue is critical for receptor interaction. Yet this variant is one of the most common impurities in low-grade synthesis batches. Using such a product in a research protocol doesn't just produce weak results; it produces results that cannot be compared to published literature, because the molecular entity being tested is fundamentally different.
Real Peptides manufactures every peptide through small-batch synthesis with exact amino-acid sequencing verified by mass spectrometry before release. You can view batch-specific purity data for GHRP-6 and compare it to the sequencing standards referenced in peer-reviewed growth hormone research. The molecular weight, retention time, and purity profile match published pharmacokinetic studies because the synthesis process is identical to what academic institutions use.
GHRP-6 vs GHRP-2, Ipamorelin, and Hexarelin: Receptor Selectivity and Side-Effect Profiles
GRHP-6 is one of several synthetic growth hormone secretagogues used in peptide research, and understanding how it differs from structurally similar compounds. GHRP-2, ipamorelin, and hexarelin. Is essential for protocol design. All four peptides bind to GHS-R1a receptors and stimulate growth hormone release, but they differ significantly in receptor selectivity, off-target activity, and side-effect profiles.
GHRP-6
High
Moderate to Strong. Increases food intake 30–50% in rodent models at doses >150 mcg/kg
Minimal. Does not significantly elevate cortisol or prolactin at standard doses
Low. Sustained use does not reduce GH response over 4–6 weeks
100–300 mcg/kg subcutaneous
GHRP-2
Mild. Smaller appetite effect than GHRP-6, increases intake 10–20% at equivalent doses
Minimal
Low
Ipamorelin
Moderate
None. Does not increase food intake at any dose tested in rodent models
None. Highly selective, no cortisol or prolactin elevation
Very Low. No desensitization observed in 12-week rodent studies
200–500 mcg/kg subcutaneous
Hexarelin
Very High
Mild
Moderate. Dose-dependent cortisol and prolactin elevation at doses >200 mcg/kg
High. GH response diminishes significantly after 2–3 weeks of daily use
100–200 mcg/kg subcutaneous
GRHP-6's defining characteristic is its strong appetite-stimulating effect, mediated through GHS-R1a activation in the arcuate nucleus of the hypothalamus. This makes GHRP-6 particularly useful in research models studying cachexia (muscle wasting), anorexia, or metabolic recovery after caloric restriction. Contexts where increased food intake is a desired outcome. In contrast, ipamorelin produces equivalent growth hormone release without affecting appetite, making it the preferred secretagogue in studies where food intake must remain constant.
Hexarelin, while producing the highest growth hormone peaks of the four peptides, also activates non-GHS-R1a pathways that elevate cortisol and prolactin. This off-target activity complicates interpretation in metabolic studies and introduces confounding endocrine variables. Additionally, hexarelin exhibits rapid desensitization: daily administration for more than two weeks in rodent models produces progressively smaller growth hormone responses, likely due to GHS-R1a receptor downregulation or internalization. GHRP-6 and GHRP-2 do not show this pattern. Growth hormone response remains stable across 4–6 weeks of daily dosing.
Ipamorelin's selectivity comes at a cost: it has lower receptor affinity than GHRP-6 or hexarelin, requiring higher doses to produce equivalent growth hormone peaks. In head-to-head comparisons, 300 mcg/kg ipamorelin produces growth hormone elevation roughly equivalent to 150 mcg/kg GHRP-6. The trade-off is fewer side effects versus higher compound consumption per study.
Our experience supplying secretagogues to metabolic research labs shows a clear protocol pattern: GHRP-6 is chosen when appetite modulation is part of the research question, Ipamorelin is chosen when growth hormone stimulation must occur without confounding food intake changes, and Hexarelin is used only in short-term acute studies where maximal growth hormone response is needed and cortisol elevation is not a disqualifying factor.
GHRP-6 Storage, Reconstitution, and Stability: Why Temperature Excursions Destroy Peptide Integrity
Peptide stability is not a packaging convenience. It's a molecular necessity. GHRP-6, like all peptides, is a protein structure held together by peptide bonds that are vulnerable to hydrolysis (water-mediated breakdown), oxidation, and temperature-induced denaturation. A vial of GHRP-6 that looks clear and sterile can be completely inactive if storage protocols were violated at any point between synthesis and use.
Lyophilized (freeze-dried) GHRP-6 must be stored at −20°C (standard freezer temperature) to prevent peptide bond hydrolysis and oxidation. At this temperature, high-purity GHRP-6 remains stable for 24–36 months from the date of manufacture. Storing lyophilized peptides at refrigerator temperature (2–8°C) reduces stability to 12–18 months, and storing them at room temperature (20–25°C) degrades the peptide by 15–30% within six months. Temperature excursions above 25°C. Such as leaving a vial in a delivery truck during summer or storing it in a non-climate-controlled lab space. Accelerate degradation exponentially.
Once reconstituted with bacteriostatic water (sterile water containing 0.9% benzyl alcohol as a preservative), GHRP-6 must be stored at 2–8°C and used within 28 days. Reconstituted peptides are aqueous solutions, which means hydrolysis occurs continuously in the presence of water. Refrigeration slows this reaction but does not stop it. After 28 days, even refrigerated reconstituted GHRP-6 loses 10–20% potency, and by 60 days, the peptide may be 40–60% degraded into inactive fragments.
The biggest mistake researchers make with GHRP-6 isn't contamination. It's injecting air into the vial while drawing the solution. The resulting pressure differential pulls contaminants back through the needle on every subsequent draw, and repeated exposure to air accelerates oxidation of the tryptophan residues at positions 2 and 4, which are the most oxidation-prone amino acids in the GHRP-6 sequence. Best practice: use a separate sterile needle to vent the vial (release pressure) while drawing solution with the dosing needle, and discard vials after 20–25 draws regardless of remaining volume.
Reconstitution itself is straightforward but intolerant of error. Add bacteriostatic water slowly down the side of the vial. Never inject it directly onto the lyophilized peptide cake, as the mechanical force can shear peptide bonds. Swirl gently to dissolve; do not shake. If the solution remains cloudy or contains visible particles after five minutes of gentle swirling, the peptide has aggregated (clumped together due to improper storage or freeze-thaw cycles before lyophilization) and should not be used. Aggregated peptides have unpredictable bioavailability and can trigger immune responses in animal models.
Every batch of peptides from Real Peptides ships in vacuum-sealed vials with desiccant packs and temperature-monitoring labels. If the label indicates a temperature excursion above 8°C during transit, we replace the order at no cost. There is no point conducting research with degraded peptides, and no way to visually confirm potency loss without mass spectrometry.
Key Takeaways
GHRP-6 is a synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) that functions as a ghrelin receptor agonist, binding to GHS-R1a receptors to stimulate pulsatile growth hormone release.
The two D-amino acids in GHRP-6 (D-Trp at position 2, D-Phe at position 5) confer protease resistance, extending receptor-binding activity to 90–120 minutes versus 30 minutes for endogenous ghrelin.
Research-grade GHRP-6 requires >98% purity by HPLC with mass spectrometry confirmation. Peptides below 95% purity contain deletion sequences and acetylated fragments that do not bind to GHS-R1a receptors.
GHRP-6 produces dose-dependent growth hormone release (8–12× baseline at 100 mcg/kg, 15–20× baseline at 300 mcg/kg in rodent models) but also stimulates appetite through hypothalamic GHS-R1a activation.
Lyophilized GHRP-6 must be stored at −20°C for long-term stability; once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 28 days to prevent hydrolysis-driven potency loss.
What If: GHRP-6 Research Scenarios
What If the Reconstituted GHRP-6 Solution Turns Cloudy After One Week in the Refrigerator?
Discard the vial immediately. Cloudiness indicates peptide aggregation (clumping), which occurs when peptide chains unfold and bind to each other rather than remaining in solution. Aggregated peptides have unpredictable bioavailability, reduced receptor-binding affinity, and can trigger immune responses in animal models that interfere with study outcomes. Cloudiness after one week suggests either a freeze-thaw cycle occurred before lyophilization (degrading the peptide structure before you received it), the vial was stored above 8°C before reconstitution, or the bacteriostatic water used for reconstitution was contaminated. Always reconstitute GHRP-6 with fresh bacteriostatic water from a sealed vial, never reuse partially used bacteriostatic water across multiple peptide reconstitutions, and confirm the lyophilized peptide was stored at −20°C from receipt until reconstitution.
What If Growth Hormone Response Is Lower Than Expected Based on Published Literature?
Verify three variables before concluding the peptide is inactive: dose accuracy, injection timing relative to baseline growth hormone levels, and peptide purity. Rodent growth hormone secretion follows a circadian rhythm with natural peaks occurring every 3–4 hours. Administering GHRP-6 during an endogenous peak produces a smaller observed delta than administration during a trough. Best practice is to standardize injection timing to early morning after an overnight fast, when baseline growth hormone is low and response magnitude is most consistent. If timing and dose are correct but response remains low, request a certificate of analysis (CoA) from your supplier showing HPLC purity and mass spectrometry confirmation. Peptides below 95% purity produce 30–50% lower growth hormone peaks than literature values because a significant fraction of the injected dose is inactive deletion sequences.
What If GHRP-6 Is Needed for a Study Lasting Longer Than Four Weeks — Does Receptor Desensitization Occur?
No. GHRP-6 does not exhibit the receptor desensitization seen with hexarelin during chronic administration. Studies using daily GHRP-6 dosing in rodent models for up to six weeks show stable growth hormone response across the study duration, with no significant decline in peak GH levels or area under the curve (AUC). The GHS-R1a receptor does not downregulate in response to GHRP-6 the way it does with hexarelin, likely because GHRP-6 has lower absolute receptor affinity and does not activate the same off-target pathways that trigger compensatory receptor internalization. For studies extending beyond six weeks, consider pulsed dosing (three days on, one day off) to preserve physiological growth hormone pulsatility and prevent any potential long-term receptor adaptation that hasn't been characterized in published literature.
The Mechanistic Truth About GHRP-6
Here's the honest answer: GHRP-6 works because it's a better ghrelin than ghrelin itself. It binds the same receptor with higher affinity, resists the enzymes that would normally destroy it, and produces growth hormone pulses that are larger and longer than anything the body generates naturally. That's not speculation, it's receptor pharmacology. The peptide's effectiveness is entirely dependent on exact amino-acid sequencing and storage integrity. There is no margin for error. A GHRP-6 variant missing the C-terminal amide or containing L-tryptophan instead of D-tryptophan at position 2 is not 'slightly less effective,' it's functionally inactive.
The difference between research-grade GHRP-6 and bulk peptide powder is not about branding or price. It's about whether the molecular structure matches what was used in the published studies you're trying to replicate. If your supplier cannot provide batch-specific HPLC chromatograms and mass spectrometry data showing >98% purity and exact molecular weight confirmation, you're not conducting peptide research, you're conducting impurity research. The only studies that produce replicable, publishable data are the ones using peptides synthesized and stored to the same standards as the original pharmacokinetic trials.
Real Peptides supplies GHRP-6 synthesized through solid-phase peptide synthesis with individual amino-acid coupling verified at each step. Every batch includes a certificate of analysis with HPLC purity percentage, mass spectrometry molecular weight confirmation, and sterility testing results. The synthesis process is identical to what academic institutions use, which is why growth hormone response data from studies using our GHRP-6 aligns with published literature values rather than showing unexplained variability. For researchers designing growth hormone, metabolic, or appetite regulation protocols, explore our full catalog of secretagogues and bioactive peptides at Real Peptides. Every compound is manufactured to the same sequencing and purity standards that make research outcomes reproducible.
If the peptide you're using doesn't come with verified purity data, the variability in your results isn't biological. It's chemical. And no amount of experimental design sophistication can compensate for starting with the wrong molecule.
Frequently Asked Questions
GHRP-6 binds to the same GHS-R1a receptors as ghrelin but with higher affinity and significantly longer duration of action due to D-amino acid incorporation at positions 2 and 5, which confers resistance to enzymatic degradation by dipeptidyl peptidase-IV and other proteases. While endogenous ghrelin has a circulating half-life of approximately 30 minutes, GHRP-6 maintains receptor-binding activity for 90–120 minutes, producing sustained intracellular signaling through Gq protein coupling and calcium mobilization that results in larger and longer growth hormone pulses than natural ghrelin can generate.
Yes — GHRP-6 does not exhibit the receptor desensitization observed with hexarelin during chronic administration. Rodent studies using daily GHRP-6 dosing for up to six weeks show stable growth hormone response with no significant decline in peak GH levels or area under the curve, indicating that GHS-R1a receptors do not downregulate in response to sustained GHRP-6 exposure. For studies extending beyond six weeks, pulsed dosing schedules (three days on, one day off) are often used as a precautionary measure to preserve physiological pulsatility, though published data does not indicate this is necessary for GHRP-6 specifically.
Research-grade GHRP-6 synthesized to >98% purity with verified amino-acid sequencing and mass spectrometry confirmation typically costs 2–4 times more than bulk peptide powder sold without certificates of analysis or purity verification. The price difference reflects the cost of individual amino-acid coupling verification during solid-phase synthesis, reverse-phase HPLC purification to remove deletion sequences and synthesis byproducts, and batch-specific analytical testing. Peptides below 95% purity produce 30–50% lower growth hormone responses than literature values because a significant fraction of the dose is inactive truncated fragments — using low-purity peptides does not save money if the research outcomes are not reproducible or comparable to published studies.
GHRP-6 increases appetite through direct activation of GHS-R1a receptors in the hypothalamic arcuate nucleus, which regulates hunger signaling independently of growth hormone release. This orexigenic effect cannot be separated from the growth hormone response because both are mediated by the same receptor — GHRP-6 binding to GHS-R1a triggers growth hormone secretion in the pituitary and hunger signaling in the hypothalamus simultaneously. Rodent studies show food intake increases by 30–50% at doses above 150 mcg/kg within 60–90 minutes of administration. Researchers studying metabolic outcomes where caloric intake must remain constant typically use ipamorelin instead, which produces equivalent growth hormone release without affecting appetite.
Storing lyophilized GHRP-6 at room temperature (20–25°C) instead of −20°C accelerates peptide bond hydrolysis and oxidation, degrading the peptide by 15–30% within six months and rendering it significantly less potent or inactive within 12–18 months. Temperature excursions above 25°C — such as exposure to summer heat during shipping or storage in non-climate-controlled spaces — cause exponential degradation rates that can reduce potency by 40–60% in a matter of weeks. Because peptide degradation is not visually detectable (the powder still appears white and the reconstituted solution remains clear), researchers using improperly stored GHRP-6 often attribute low growth hormone responses to biological variation rather than peptide instability.
Ipamorelin produces equivalent growth hormone release to GHRP-6 without stimulating appetite because it has higher GHS-R1a receptor selectivity and does not activate the hypothalamic hunger signaling pathways that GHRP-6 engages. In head-to-head comparisons, 300 mcg/kg ipamorelin produces growth hormone elevation roughly equivalent to 150 mcg/kg GHRP-6, meaning ipamorelin requires higher doses to achieve the same effect. The trade-off is fewer confounding variables (no appetite increase, no cortisol or prolactin elevation) versus higher compound consumption per study. Researchers choose GHRP-6 when appetite modulation is part of the research question and ipamorelin when growth hormone stimulation must occur without affecting food intake.
Purity percentage reflects the proportion of a peptide sample that is the correct target sequence versus truncated sequences (deletion variants missing one or more amino acids), synthesis byproducts, or residual solvents like trifluoroacetic acid from the purification process. GHRP-6 at 98% purity means 98% of the sample is the complete His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 sequence, and 2% is impurities. Peptides below 95% purity contain significant amounts of des-amino variants — such as des-Lys GHRP-6 (missing the lysine at position 6) — which have nearly zero GHS-R1a receptor-binding affinity. Using such peptides produces growth hormone responses 30–50% lower than published literature values because a substantial fraction of the injected dose is pharmacologically inactive.
No — refreezing reconstituted GHRP-6 causes ice crystal formation that physically shears peptide bonds and denatures the protein structure, rendering the peptide partially or completely inactive. Once reconstituted with bacteriostatic water, the peptide must remain refrigerated at 2–8°C and used within 28 days, as hydrolysis occurs continuously in aqueous solution and refrigeration only slows the reaction without stopping it. After 28 days, even properly refrigerated GHRP-6 loses 10–20% potency, and by 60 days the peptide may be 40–60% degraded into inactive fragments. Researchers should calculate dosing schedules to consume reconstituted peptides within the 28-day window or reconstitute smaller aliquots from multiple lyophilized vials rather than attempting to extend the lifespan of a single reconstituted vial.
Outcome variability in GHRP-6 studies with identical protocols is almost always attributable to differences in peptide purity, amino-acid sequencing accuracy, or storage integrity rather than biological variation. GHRP-6 containing L-tryptophan instead of D-tryptophan at position 2, missing the C-terminal amide group, or degraded due to temperature excursions during storage produces significantly lower growth hormone responses than properly synthesized and stored peptides — yet these molecular differences are not detectable without mass spectrometry and HPLC analysis. Researchers using peptides from suppliers that do not provide batch-specific certificates of analysis showing >98% purity and exact molecular weight confirmation are testing chemically inconsistent compounds, which makes comparing results to published literature or replicating outcomes across studies impossible.
GHRP-6 should be administered during periods of low baseline growth hormone to maximize the observed response magnitude — typically early morning after an overnight fast, when endogenous growth hormone pulsatility is at a trough. Rodent growth hormone secretion follows a circadian rhythm with natural peaks every 3–4 hours; administering GHRP-6 during an endogenous peak produces a smaller delta between baseline and post-injection levels than administration during a trough, even though the absolute growth hormone stimulation is the same. Standardizing injection timing to the same circadian phase across all study days reduces intra-study variability and makes growth hormone response data more comparable to published literature, which typically uses fasted morning dosing as the protocol standard.